As Australia’s largest manufacturer of sterilants, disinfectants and professional cleaning technologies, Whiteley have been protecting lives and livelihoods since 1933. In 2023, Whiteley celebrates 90 years of business and best practise, continuing its commitment to innovation in technology and service.
Take a trip with us down memory lane as we recognise our rich history and 90 years of achievements.
In 1933, the Australian General Disinfectant Company (AGDC) was founded; this marked the beginning of Whiteley Corporation. The AGDC supplied hygiene products and processes for the entertainment industry and public amenities. The company progressively developed a complete range of deodorants, disinfectants, insecticides, pest control chemicals and cleaning products, becoming the first Australian company to specialise in what are known today as Sanitation chemicals.
During the years of the Second World War, the product range of the AGDC was extended to include personal hygiene products including antiseptics for the war efforts.
During the 1950s, the product range expanded to include chemical products for building maintenance. The manufacture of floor sealers, polishers and waxes for hard floors became a major objective of the AGDC. The company has made many advances in introducing improved methods for floor maintenance, expanding to a range that includes soft flooring and carpet care.
The AGDC made a significant contribution to the formulation of the first chemical trade organisation – the Association of Sanitation Chemical Manufacturers.
In 1971, the Whiteley family became involved in the business initially through Mr Reginald K Whiteley. The Whiteley family then acquired the controlling interest in the company with Mr Reginald K Whiteley having a more active involvement. Throughout the 70’s his son Greg commences permanent work within the business and in 1976, the company name is changed to Whiteley Chemicals Australia.
In 1987, research collaboration with Sydney University and Professor Yvonne Cossart leads to the launch of key products in the Whiteley portfolio, including AIDAL PLUS® and Viraclean®.
In 1995, the company transferred its manufacturing to a purpose-built, world-class facility at Tomago, in the hunter region of New South Wales.
The site is licensed by Standards Australia, the Therapeutic Goods Administration (TGA) and other relevant regulatory authorities.
In 2002, after extensive years of research and development, Whiteley launched Matrix® Biofilm Remover. Matrix® is a success story for the company as it was the first proven wet surface biofilm remover launched and the result of collaborative research with the University of Sydney. The ongoing research and commitment continues to support Matrix® reputation in the field.
In March, 2005 Whiteley Industries changes its name to Whiteley Corporation Pty Ltd. This was a strategic decision aimed at better encapsulating both the medical and industrial divisions of the organisation
In 2016, Whiteley launched the world’s first dry surface biofilm remover, Surfex, and proudly won awards for the innovative technology that contributed to the launch.
The SARS-CoV2 pandemic resulted in substantial growth for the business, proudly recognised locally through Hunter Business Awards and Hunter Manufacturer awards.
In June 2023, Whiteley Corporation recognises and celebrates 90 years of business. Looking forward, Whiteley will continue to achieve high standards in manufacturing, distribution, and technical support. Our business remains committed to innovation, best practise and protecting lives and livelihoods.
Stay up to date on the latest Whiteley news on research, collaborations, events, product advancements and news from the various industry sectors we work.
Celebrating 90 years of business with Export Customers 22nd September
Vale Professor Mary-Louise McLaws 17th March 1953 – 12th August
Hand hygiene saves millions of lives every year when performed
International Women’s Day (IWD) is a day of celebration advocating
Whiteley offers advice, training and practical support for all of your infection prevention, medical device reprocessing, and professional cleaning needs.
You can view our product safety data sheets, technical bulletins and find out about the products from our range.
Speaker: Doctor Arthika Manoharan
Qualifications: Postdoctoral Research Fellow at University of Sydney
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at The University of Sydney Infectious Diseases Institute, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Professor Slade Jensen
Qualifications: B.Med.Sc. (USyd) PhD. (USyd). FASM
Speaker Profile:
Slade is a Professor of Microbiology and Infectious Diseases in the School of Medicine, Western Sydney University and Research Director of the Antibiotic Resistance and Mobile Elements Group, and the Limb Preservation and Wound Research Group, both of which are based at the Ingham Institute for Applied Medical Research. He obtained a Ph.D. from the University of Sydney focused on the role of horizontal gene transfer in bacterial evolution. His current research interests include the development of novel antimicrobials, the evolution of antibiotic resistance in hospital pathogens, such as ‘Golden Staph’, and the role of host-microbe interactions in disease progression, particularly in the context of diabetes-related foot ulcers.
Topic: Microbes, biofilms and diabetes-related foot ulcers
Presentation Outline: Slade will discuss how his team’s research has assisted in changing the understanding of the pathology of chronic ulceration in diabetic foot infections, from that of infection with planktonic bacteria to that of infection with biofilm. Due to the resistance of biofilms to antimicrobial penetration, increased emphasis is now given to removal of adequate volumes of tissue with debridement and the use of anti-biofilm compounds.
Speaker: Professor Kate Moore
Qualifications: MB BS Syd, MD Liv, FRCOG, FRANZCOG, CU
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at the University of Sydney, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Associate Professor Greg Whiteley
Qualifications: FEHA, MASM, MSHEA, PhD, M Safety Sc, B App, Dip AICD
Speaker Profile:
Dr Greg Whiteley is an Adjunct Associate Professor in the Faculty of Medicine and Health at the University of Sydney, a Fellow in the School of Medicine at Western Sydney University and is also the Executive Chairman of Whiteley Corporation. Assoc. Prof Whiteley’s qualifications include a Bachelor of Applied Science (Hawkesbury Agricultural College), a Master of Safety Science (University of New South Wales), a Diploma from the Australian Institute of Company Directors (University of New England) and a PhD (Western Sydney University).
Dr Whiteley is a Life Fellow of Environmental Health Australia, a Member of the Society of Healthcare Epidemiology of America and is a Member of the Australian Society of Microbiology. He currently serves as a director of the trade association known as ACCORD Australia, and also as an expert consultant to the Infection Control Committee for the Australian Dental Association. He has previously served on HE-023 with Standards Australia.
His on-going research interests focus on biofilms found within healthcare settings, healthcare hygiene and the cleanliness of medical devices. Findings from this research team include publications outlining the extent of biofilm problems within healthcare and other settings, monitoring solutions including ATP testing, and extensive findings on the cleaning and disinfecting implications from biofilms on healthcare surfaces and reusable medical devices.
Dr Whiteley has previously been an Industry Partner for an ARC Grant in conjunction with Macquarie University, a Collaboration Partner Study Director for an iMCRC Grant with the School of Medicine at Sydney University, the Study Director of a CRC-P Grant investigating novel diagnostic and treatment options for wound care co-jointly partnering with AMP Control and the University of Newcastle and Western Sydney University.
Dr Whiteley is currently the Executive Chairman of Whiteley Corporation. He bears ultimate responsibility under Commonwealth Legislation for the Therapeutic Goods registrations and the manufacturing license of the manufacturing location in Tomago. Dr Whiteley has additionally co-authored many patents and peer reviewed publications.
Topic: Advances in Biofilm Testing
Presentation Outline: This topic will provide an overview into key lessons and research findings on dry surface and wet surface biofilms and their impact on critical healthcare departments. Published research on the presence of biofilms containing viable multi-resistant organisms and the critical role of rigorous cleaning processes to prevent hospital acquired infections (HAI’s). Understanding why cleaning protocols must adapt to account for our new logic of the role of biofilms in bacterial survival and transmission of infections.